RT Journal Article
SR Electronic
T1 Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1289
OP 1295
DO 10.1183/09031936.00063514
VO 44
IS 5
A1 Jung-Wan Yoo
A1 Kyung-Wook Jo
A1 Bo-Hyung Kang
A1 Mi Young Kim
A1 Bin Yoo
A1 Chang-Keun Lee
A1 Yong-Gil Kim
A1 Suk-Kyun Yang
A1 Jeong-Sik Byeon
A1 Kyung-Jo Kim
A1 Byong Duk Ye
A1 Tae Sun Shim
YR 2014
UL http://erj.ersjournals.com/content/44/5/1289.abstract
AB Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthritis (n = 320), and ankylosing spondylitis (n = 389). TB and NTM disease were diagnosed at baseline screening in four and three patients, respectively, and developed during anti-TNF-α therapy in 19 and six patients, respectively. The incidence rate of TB and NTM disease was 747.7 per 100 000 and 238.2 per 100 000 person-years, respectively. Patients with NTM disease were older, with a greater proportion of females. All cases of NTM disease involved the lung, with rheumatoid arthritis (83.3%) being the most frequent underlying disease. The most common radiological feature was consolidation in NTM disease, and honeycombing was present in two rheumatoid arthritis patients with NTM disease. The most common pathogen was Mycobacterium intracellulare (n = 3) followed by Mycobacterium avium (n = 2). Both the NTM and TB group showed favourable outcomes. The clinical characteristics differed between NTM disease and TB that developed on anti-TNF-α agents, but clinical outcomes were favourable in both diseases. Clinical characteristics differ between nontuberculous mycobacterial disease and TB that develop on anti-TNF-α agents http://ow.ly/xSQ0o